News Industry News ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy July 27, 2015
News Industry News Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority June 22, 2015
News Industry News Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treat May 26, 2015